Sargent Bickham Lagudis’s Idexx Laboratories IDXX Stock Holding History

Sargent Bickham Lagudis’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$87.7K	Buy	215 +49	+30%	+$19K	0.01%	357
2022 Q3	$54K	Hold	166	–	–	﹤0.01%	398
2022 Q2	$59K	Sell	166 -100	-38%	-$40.8K	0.01%	388
2022 Q1	$146K	Sell	266 -118	-31%	-$62.1K	0.01%	287
2021 Q4	$253K	Hold	384	–	–	0.02%	223
2021 Q3	$239K	Sell	384 -59	-13%	-$39.6K	0.02%	229
2021 Q2	$280K	Sell	443 -40	-8%	-$22.1K	0.02%	221
2021 Q1	$236K	Sell	483 -221	-31%	-$111K	0.02%	219
2020 Q4	$352K	Sell	704 -105	-13%	-$47K	0.03%	182
2020 Q3	$318K	Buy	809 +772	+2,086%	+$285K	0.03%	175
2020 Q2	$12K	Hold	37	–	–	﹤0.01%	552
2020 Q1	$9K	Buy	+37	New	+$9.66K	﹤0.01%	567
2017 Q2	–	Sell	-6	Closed	-$1K	–	782
2017 Q1	$1K	Buy	+6	New	+$827	﹤0.01%	723

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sargent Bickham Lagudis's IDXX Position: Q4 2022 in Review

Sargent Bickham Lagudis increased its Idexx Laboratories (IDXX) stake by 30% in Q4 2022, buying an estimated $19K and bringing the position to 215 shares worth $87.7K. The position accounts for 0.01% of the portfolio, ranked #357.

Sargent Bickham Lagudis first reported a position in IDXX in Q1 2017 and has held it in 13 quarters since. The position peaked at $352K in Q4 2020. 999 funds tracked by Wall St. Rank hold IDXX as of Q4 2022.

Sargent Bickham Lagudis held 215 shares of Idexx Laboratories worth $87.7K as of Q4 2022.
Sargent Bickham Lagudis bought 49 Idexx Laboratories shares in Q4 2022, an estimated $19K.
Idexx Laboratories made up 0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #357 holding.
Sargent Bickham Lagudis first reported a position in Idexx Laboratories in Q1 2017 and has held it in 13 quarters since.
Sargent Bickham Lagudis's Idexx Laboratories position peaked at $352K in Q4 2020.
999 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.